Media & Investors
Transparency is important to us. Find important information about Kuros Biosciences here – from our corporate documents to our current share price.
13 Apr 2021
Kuros Biosciences treats first patient in clinical trial of MagnetOs Putty for posterolateral spine fusion
08 Apr 2021
Kuros Biosciences announces treatment of first patient in Australia with MagnetOs for spine fusion
Reports & corporate governance
Kuros Biosciences is fully committed to good corporate governance and adherence to high ethical standards. Our principles and rules on corporate governance and ethical conduct are articulated in the Articles of Association, the Internal Regulations, the charters of the committees of our board of directors, and our code of conduct.
Olav Zilian, MD, PhD, EMBA
Mirabaud Securities Ltd
David Sherman, Ph.D.(AC)
Please use the button below to view and download Analyst reports
|Mar 18, 2021||Kuros will publish its Annual Report for 2020|
|Apr 19, 2021||Kuros will hold its Annual Shareholders' Meeting|
|Aug 11, 2021||Kuros will publish its Half Year Report for H1 2021|